Stephen Welton
Internal Medicine · Sikeston, MONPI 1922078328
Payments from drug & device makers
Across 303 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$829
- Eisai Inc.$581
- Amgen$515
- Novo Nordisk$507
- Lilly USA, LLC$467
- Novartis$348
- plus $3K from 36 others
What the payments were for
- Food & beverage$6,119100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,119 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 129 | $122,657 |
| MounjaroTirzepatide | 44 | $47,023 |
| EliquisApixaban | 54 | $42,547 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $30,878 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $29,314 |
| FarxigaDapagliflozin Propanediol | 37 | $28,182 |
| TrintellixVortioxetine Hydrobromide | 56 | $27,935 |
| MyrbetriqMirabegron | 78 | $24,989 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 582 | $21,376 |
| XareltoRivaroxaban | 18 | $20,024 |
| TradjentaLinagliptin | 19 | $17,412 |
| EntrestoSacubitril/Valsartan | 18 | $16,750 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $16,050 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $12,852 |
| VascepaIcosapent Ethyl | 26 | $11,855 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $507 | $122,657129 claims |
| Lilly USA, LLCMounjaro | $467 | $47,02344 claims |
| PfizerEliquis | $129 | $42,54754 claims |
| GSKTrelegy Ellipta, Shingrix | $54 | $32,44353 claims |
| AstraZenecaFarxiga, Symbicort | $127 | $31,50651 claims |
| Boehringer IngelheimTradjenta, Combivent Respimat | $62 | $30,26437 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $45 | $27,93556 claims |
| Astellas Pharma US IncMyrbetriq | $89 | $24,98978 claims |
| MerckJanuvia, Belsomra | $114 | $20,25637 claims |
| Johnson & JohnsonXarelto | $134 | $20,02418 claims |
| NovartisEntresto | $348 | $16,75018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Sikeston
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.